Lisa Salberg and Dr. Michael Ayers explore the rapidly evolving world of HCM treatment, from myosin inhibitors and clinical trials to AFib management and patient-centered care. The episode also dives into advocacy, drug safety concerns, and why personalized treatment strategies matter more than ever for people living with hypertrophic cardiomyopathy.
This conversation was recorded May 15, 2026.
